Published in Curr Drug Targets Infect Disord on June 01, 2005
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15
Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med (2007) 2.20
Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques. Immunogenetics (2007) 1.87
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology (2009) 1.42
Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One (2011) 1.24
HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci U S A (2007) 1.09
Highly multiplexed quantitation of gene expression on single cells. J Immunol Methods (2013) 1.07
Large animal models of hematopoietic stem cell gene therapy. Gene Ther (2010) 1.03
Comparison of the effects of pathogenic simian human immunodeficiency virus strains SHIV-89.6P and SHIV-KU2 in cynomolgus macaques. AIDS Res Hum Retroviruses (2008) 1.01
Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol (2008) 1.00
Isolation and characterization of intestinal epithelial cells from normal and SIV-infected rhesus macaques. PLoS One (2012) 0.99
Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infect Immun (2006) 0.97
Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2012) 0.97
Pulmonary vascular lesions are common in SIV- and SHIV-env-infected macaques. AIDS Res Hum Retroviruses (2010) 0.95
Simian immunodeficiency virus SIVrcm, a unique CCR2-tropic virus, selectively depletes memory CD4+ T cells in pigtailed macaques through expanded coreceptor usage in vivo. J Virol (2009) 0.95
Characterization of the major histocompatibility complex class II DOB, DPB1, and DQB1 alleles in cynomolgus macaques of Vietnamese origin. Immunogenetics (2010) 0.88
Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology (2009) 0.88
Coreceptor use in nonhuman primate models of HIV infection. J Transl Med (2011) 0.87
The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. Virology (2011) 0.87
Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV. Virology (2006) 0.85
Synergistic effect of human CycT1 and CRM1 on HIV-1 propagation in rat T cells and macrophages. Retrovirology (2009) 0.84
Nonhuman primate lung decellularization and recellularization using a specialized large-organ bioreactor. J Vis Exp (2013) 0.84
Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration. Virology (2007) 0.82
Replication potentials of HIV-1/HSIV in PBMCs from northern pig-tailed macaque (Macaca leonina). Dongwuxue Yanjiu (2014) 0.81
Nef gene evolution from a single transmitted strain in acute SIV infection. Retrovirology (2009) 0.81
Longitudinal analysis reveals characteristically high proportions of bacterial vaginosis-associated bacteria and temporal variability of vaginal microbiota in northern pig-tailed macaques (Macaca leonina). Dongwuxue Yanjiu (2015) 0.79
Longitudinal cerebral metabolic changes in pig-tailed macaques infected with the neurovirulent virus SIVsmmFGb. J Neurovirol (2014) 0.78
Molecular cloning and anti-HIV-1 activities of APOBEC3s from northern pig-tailed macaques (Macaca leonina). Dongwuxue Yanjiu (2016) 0.77
Evaluation of cynomolgus macaque (Macaca fascicularis) endogenous retrovirus expression following simian immunodeficiency virus infection. PLoS One (2012) 0.77
Delivery strategies for novel vaccine formulations. World J Virol (2012) 0.76
Humanizing NOD/SCID/IL-2Rγnull (NSG) mice using busulfan and retro-orbital injection of umbilical cord blood-derived CD34(+) cells. Blood Res (2016) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 6.30
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med (2004) 5.49
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (1990) 5.33
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol (2005) 5.25
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature (1986) 4.35
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med (1998) 4.13
Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science (1999) 4.09
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1992) 3.94
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74
Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2003) 3.64
Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol (2000) 3.48
Vaccination in humans generates broad T cell cytokine responses. J Immunol (2004) 3.27
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A (1995) 3.23
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS (2002) 3.19
Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol (1999) 3.17
Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol (1991) 3.05
A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93
Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol (1996) 2.86
Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science (1992) 2.83
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
Isolation of a lentivirus from a macaque with lymphoma: comparison with HTLV-III/LAV and other lentiviruses. J Virol (1986) 2.77
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
HIV vaccines 1983-2003. Nat Med (2003) 2.59
Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med (2002) 2.51
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol (1998) 2.49
Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol (2001) 2.43
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol (2000) 2.37
Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii). J Virol (2003) 2.12
Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci U S A (2004) 2.09
The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today (2000) 2.03
Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol (1990) 1.86
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol (2002) 1.80